LY 4006895
Alternative Names: LY-4006895Latest Information Update: 12 Nov 2024
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 24 Oct 2024 Preclinical trials in Alzheimer's disease in USA (IV) (NCT06657768)
- 24 Oct 2024 Eli Lilly and Company plans a phase I trial for Alzheimer Disease (In volunteers) in the USA (IV) in October 2024 (NCT06657768)